FEELM
19.5.2022 10:43:11 CEST | Business Wire | Press release
FEELM, the flagship atomization tech brand belonging to SMOORE, today released its “Race to Zero” plan and roadmap to carbon neutrality. The plan brings forward FEELM’s ambitions to achieve net-zero carbon emissions by 2050 in its direct production activities and indirect purchased energy (scope 1&2). Meanwhile, FEELM makes a commitment that renewable energies will account for 30% of its total energy consumption by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005482/en/
As one of China’s first atomization tech brands to make a carbon neutrality commitment, FEELM pledges to reach net zero in full supply chain and full product lifespan by developing sustainable products, improving energy efficiency with automated production, supporting the supply chain in decarbonization, and increasing renewable energies and eco-friendly materials.
FEELM, being the world ‘s largest closed vape system solution provider, plays a significant role in the global vaping supply chain. On the one hand, it provides millions of global consumers with premium product experience by virtue of partnership with vaping brands around the world; on the other hand, FEELM has been leading a sustainable revolution in the supply chain.
Leading on Sustainability by introducing FUTURE series solutions
FEELM has been leading on sustainability and green product innovations, which is the industry’s driving force towards carbon neutrality. Committed to providing global customers with zero carbon technologies, FEELM has introduced FUTURE series solutions, which feature recyclability, disassemblability, biodegradability and minimalist design.
Since 2019, FEELM has already pioneered a number of green vaping solutions. For example, it won iF Design Award 2020 for disposable paper e-cigarette, which is made up of spiral composite paper tube, improving the degradability rate to approximately 76% of the total volume, compared with the plastic used in traditional vaping products.
Moreover, FEELM is ready to unveil another eco-friendly non-nicotine disposable e-cigarette at Vaper Expo UK 2022 in late May . This product was awarded Red Dot Awards for Product Design 2022. Its external structure is composed of recyclable and reusable aluminum foil. It looks like a paper foil pouch and itself serves as a packaging bag, hence the reduction of packaging materials.
Supporting the Global Supply Chain in Decarbonization
In addition to developing sustainable products, FEELM has also partnered with suppliers to develop and encourage utilizing biodegradable materials while optimizing the water, electricity and gas consumption management. FEELM is also working with global customers to promote the recycling and reusing, so as to explore a feasible path towards carbon neutrality for the product lifespan and the supply chain.
As a manufacturer with environmental awareness, FEELM has supported vaping brands around the world in reducing carbon footprint and empowered our customers to achieve carbon neutrality in 2050, by eliminating unnecessary plastic packaging. For example, FEELM removed single-use plastics from packaging of one of its major customers. Having removed silicone caps from e-liquid pods, it replaced all plastic tray packaging with a pulp alternate. By 2020, FEELM had already helped this customer save over 100 tons of disposable plastics, which are equivalent to 4 million plastic bottles.
To date, China has accounted for close to 90% of global production of vaping products. As the world ‘s largest closed vape system solution provider, FEELM is devoted to facilitating carbon neutrality of the whole supply chain. It has been exploring innovative, customized carbon reduction solutions along with partners, covering a full circle from raw material supply, product design, production, consumption to recycling and reusing.
FEELM has established a series of automated production lines to optimize energy efficiency. According to its in-house greenhouse gas control and water management procedures, FEELM’s greenhouse gas emissions and water consumption have decreased by 16% and 9.4% year-on-year in 2021 respectively. For example, one of FEELM’s automatic factory has saved 2.298 million kilowatts of electricity, which is equivalent to a reduction of 601 tons of carbon emissions in 2021.
Complying with International Standards, and Making Carbon Management More Transparent
Aiming for the goal that 30% of total energy consumption will come from renewable source by 2030, FEELM is also benchmarked against the standards of international organizations. In 2022, FEELM has introduced Carbon Disclosure Project (CDP) standards to its operation and production. Moving forward, FEELM plans to set up science-based emission reduction targets by submitting to Science Based Targets initiative (SBTi).
The Science Based Targets initiative (SBTi) is a collaboration established in 2015 between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). By May 11, 2022, there are 2,466 companies from more than 70 countries and regions have joined the initiative, including 152 Chinese companies and one fifth of Forbes 500 companies.
“As a pioneer in going global in Chinese vaping industry, FEELM has been leveraging its full supply chain advantages and fundamental R&D in reducing carbon footprints. As China has pledged to be carbon neutral by 2060, FEELM is ready to fulfill its carbon neutral commitment to Chinese vaping industry, so as to explore a lower-carbon, greener and more sustainable development path with cutting-edge technologies,” said Frank Han, Senior Vice President of SMOORE and President of FEELM.
Moving forward, FEELM will continue to reduce the carbon footprints of vaping products by promoting the R&D and application of innovative green technologies and eco-friendly materials. In collaboration with suppliers and clients, FEELM is also committed to exploring and developing the recycling and reusing mechanism of vape pod cartridges, thereby playing a more significant role in the decarbonization of the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
